Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Ironwood Pharma (IRWD) Misses Q2 EPS by 4c, Revenues Miss; Offers 2018 Guidance
August 6, 2018 8:02 AM EDTIronwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.25), $0.04 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $81 million versus the consensus estimate of $82.6 million.
Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $192 million and commercial margin of 60% Terminating licensing agreement with AstraZeneca for U.S. lesinurad franchise Initiated Phase III programs with IW-3718 and linaclotide and advanced four Phase II... More